Pharmacogenomic Analysis

CLIA certified genomic and molecular testing laboratory

WE ARE COMMITTED

to helping physicians provide the best possible outcomes
so what does a

CERTIFIED LAB REALLY MEAN?

The National Reference Laboratory for Breast Health (NRLBH) is a CLIA certified, premier testing facility that is fully compliant with all regulatory requirements. Compliance to regulatory agency standards ensures accuracy, reliability and timeliness of patient test results.

NRLBH incorporates management systems that allow for prompt identification of process shifts, as well as opportunities for continuous process improvement, with Laboratory Director oversight every step of the way.

we’re committed to

HIGH QUALITY TESTING

Although we support continuous research and development for the betterment of patient health, we do not participate in registry programs. Our tenured physicians and technologists are fully dedicated to ensuring you receive a high quality test report… everytime.

We are also committed to providing our reports in a timely fashion… because we know patient management decisions are awaiting test results! We look forward to working with physicians and their patients and invite you to take a closer look at the NRLBH.

REPORTING THAT MATTERS

Our board certified pathologists and cytotechnologists can provide valuable breast health clinical information which supports healthcare professionals in making informed decisions about their patients.

the science of

PHARMACOGENOMICS

Pharmacogenomics is the study of the role of genetics in drug response.

Pharmacogenomics testing is important because it provides physicians with genetic information that can be used to guide therapeutic decisions, which may mitigate the incidence of costly adverse drug reactions (ADRs) and improve efficacy.

Key Outcomes of Pharmacogenomics Testing

  • Informed therapeutic decisions1
  • Decreased ADRs and related costs1
  • Improved patient health1

The True Costs of Adverse Drug Reactions
In addition to the billions of dollars spent on drug-related morbidity and mortality each year, there are significant “human” costs associated with ADRs:

The NRLBH is a certified CLIA laboratory committed to providing best-in-class customer service and dependable pharmacogenomics testing. Let the NRLBH help you discover the power of pharmacogenomics.

  • 4th leading cause of death in U.S. (106,000 deaths per year)2
  • 5th leading cause of illness in U.S. (2.2 million hospitalizations per year)2
  • 28% of hospitalized patients have ADRs2
  • 17% of hospitalized children have ADRs3

http://www.nrlbh.com/wp-content/themes/salient/css/fonts/svg/basic_cup.svg

QUALIFIED

knowledgeable, experienced staff; tenured scientists

http://www.nrlbh.com/wp-content/themes/salient/css/fonts/svg/basic_gear.svg

EASY

Simple swab procedure.

http://www.nrlbh.com/wp-content/themes/salient/css/fonts/svg/software_layers2.svg

COMPREHENSIVE

Capabilities include CYP2D6 and CYP2C19 genotype testing

http://www.nrlbh.com/wp-content/themes/salient/css/fonts/svg/basic_bolt.svg

FAST

Rapid turn around time; sample ships overnight

http://www.nrlbh.com/wp-content/themes/salient/css/fonts/svg/arrows_circle_downleft.svg

RESPONSIVE

Report sent to physician within 96 hours of sample receipt

http://www.nrlbh.com/wp-content/themes/salient/css/fonts/svg/basic_eye.svg

ACCESSIBLE

Medical staff available for personal consultation

did you know?

CERTAIN GENES EFFECT DRUG METABOLISM & RESPONSE

Certain genes have been identified as having an effect on drug metabolism and response. Of these, the most common are the P450 (CYP) genes. When a mutation occurs in a P450 (CYP) gene, the regular enzymatic activity that is controlled by this gene is changed, resulting in either a weakened, absent, or hyper enzymatic expression.

This change in enzyme activity is significant because it can impact the metabolism and clearance of many prescribed therapies (see chart below), potentially hindering efficacy and inducing ADRs.

For example, in the case of weakened enzymatic activity, the efficacy of certain drugs will be decreased because they cannot be efficiently converted into their active metabolites. Conversely, in the case of increased enzymatic activity, some drugs will be broken down too rapidly into their active forms, resulting in ADRs.

COMMONLY PRESCRIBED DRUGS
Affected by Enzymatic Activity of P450 (CYP) Genes

Antiarrythmics

  • Flecainide
  • Mexiletine
  • Propafenone

Antibiotics

  • Chloramphenicol

Anticancer

  • Cyclophosphamide
  • Neniposide
  • Nilutamide

Antidepressants

  • Amitriptyline
  • Citalopram
  • Clomipramine
  • Desipramine
  • Duloxetine
  • Imipramine
  • Moclobemide
  • Paroxetine
  • Sertraline
  • Venlafaxine

Antiepileptics

  • Diazepam
  • Phenobarbital
  • Phenytoin
  • Primidone
  • S-Mephenytoin

Antifungals

  • Voriconazole

Antipsychotics

  • Aripiprazole
  • Haloperidol
  • Risperidone
  • Thioridazone

Opioids

  • Codeine
  • Oxycodone
  • Tramadol

Proton Pump Inhibitors

  • Lansoprazole / Dexlansoprazole
  • Omeprazole / Esomeprazole
  • Pantoprazole
  • Rabeprazole

Other

  • Carisoprodol
  • Clopidogrel
  • Dextromethorphan
  • Hexobarbitol
  • Indomethacin
  • Mephobarbital
  • Nelfinavir
  • Ondansetron
  • Progesterone
  • Proguanil
  • Propranolol
  • R-warfarin
  • Tamoxifen

The NRLBH Promise™

Learn about affordable options with the NRLBH Promise Program

PATIENT COST GUARANTEE

When billing your insurance plan, we will accept the allowable amount determined by your plan. If the amount allowed by the insurance company is less than the cost of the test, we will not bill you for the difference. Of course, patients are responsible for the deductibles and co-pays under the terms of their insurance plans.

NRLBH PROMISE

We are committed to ensuring that our test is available to all
patients regardless of financial ability.

That is why patients who need it can receive financial help by
calling 1 (888) 403-2685.

CONTACT THE NRLBH TODAY!

The National Reference Laboratory for Breast Health develops innovative breast health services. Our services are designed to provide critical information that empowers women and their healthcare providers to take charge of and protect their breast health today and in the future.

Send us a message